We read with great interest the recent publication from Ungaro and colleagues,1 reporting the latest data from the Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) registry. These data, while raising concerns regarding the use of thiopurine and corticosteroid therapy in the SARS-CoV-2 pandemic, also provide valuable reassurance that monotherapy with anticytokine therapies, in particular those directed against tumour necrosis factor (TNF), are not associated with adverse outcomes in patients with IBD developing COVID-19. It has been postulated that anticytokine therapies may ameliorate or abrogate the ‘cytokine storm’ associated with severe COVID-19,2 with anti-IL6 strategies now approved for use.3 We have assessed the SARS-CoV-2 antibody seroprevalence in patients with IBD, receiving either intravenous anti-TNF therapy, or anti-integrin therapy, during the first wave of the pandemic in the UK. Sera from 640 patients attending for maintenance infliximab or vedolizumab infusions between April and June 2020 at the John Radcliffe Hospital (Oxford, UK) and Royal London Hospital (London, UK) were tested using the Abbott SARS-CoV-2 IgG assay. Adults (180) and paediatric (56) patients were included from London. Demographic and clinical data are summarised (online supplemental tables 1, 2). Key differences between the Oxford and London adult cohorts included ethnicity, smoking, comorbidities, disease type, concomitant thiopurines and biologic; in our data set, patients attending Royal London Hospital had significantly greater evidence for deprivation than Oxford (deprivation score 4 (3–6.3) vs 8 (6–9.3), p<0.001). Seroprevalence data were compared with available data from a contemporaneous healthy healthcare worker …

中文翻译：

---

在 IBD 中使用英夫利昔单抗或维多珠单抗维持治疗与 SARS-CoV-2 血清阳性率增加无关：英国在 2020 年大流行中的经验

我们饶有兴趣地阅读了 Ungaro 及其同事最近发表的文章，1 报告了研究排除中冠状病毒监测流行病学 (SECURE-IBD) 注册表的最新数据。这些数据虽然引起了人们对在 SARS-CoV-2 大流行中使用硫嘌呤和皮质类固醇疗法的担忧，但也提供了宝贵的保证，即抗细胞因子疗法的单一疗法，特别是针对肿瘤坏死因子 (TNF) 的疗法，与不良反应无关。发展为 COVID-19 的 IBD 患者的结果。据推测，抗细胞因子疗法可能会改善或消除与严重 COVID-19,2 相关的“细胞因子风暴”，而抗 IL6 策略现已获准使用。3 我们已经评估了 IBD 患者的 SARS-CoV-2 抗体血清阳性率, 在英国大流行的第一波期间接受静脉内抗 TNF 治疗或抗整合素治疗。2020 年 4 月至 2020 年 6 月在约翰拉德克利夫医院（英国牛津）和皇家伦敦医院（英国伦敦）接受英夫利昔单抗或维多珠单抗维持输注的 640 名患者的血清使用雅培 SARS-CoV-2 IgG 检测进行了测试。包括来自伦敦的成人 (180) 和儿童 (56) 患者。总结了人口统计学和临床​​数据（在线补充表 1、2）。牛津和伦敦成人队列之间的主要差异包括种族、吸烟、合并症、疾病类型、伴随的硫嘌呤和生物制剂；在我们的数据集中，伦敦皇家医院就诊的患者的剥夺证据明显高于牛津（剥夺评分 4 (3-6.3) 比 8 (6-9.3)，p<0.001）。